The impact of Sulpiride (600mg; a dopamine antagonist) on behavioural and electrophysiological measures of visuospatial attention and inhibition
A DAT1 genotype and DRD2 Taq1A genotype, placebo controlled, randomised, double blind, crossover designed study of the effect of Sulpiride (600mg) on visuospatial attention and cognitive control measures (recorded with electroencephalography (EEG) and behavioural tasks) in a sample of 50 healthy adults
Professor Mark Bellgrove
50 participants
Nov 11, 2016
Interventional
Conditions
Summary
This study will investigate whether temporarily reducing dopamine transmission in the healthy brain affects an individual’s spatial selective attention, that is, the direction in space (left or right) in which an individual’s visual attention naturally falls. By combining this investigation with measures of electrical activity in the brain and genetic testing, we hope to gain a deeper understanding of the mechanisms involved in spatial attention and the influence on these mechanisms of genes implicated in the structure and function of the dopamine system in the brain. Uncovering the mechanisms of spatial attention may help us better understand and treat disorders involving spatial attention deficits, including Attention Deficit Hyperactivity Disorder, which involves an impaired awareness of, and ability to respond to, objects and information in a particular area of visual space.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will attend 2 separate sessions, one week apart (on the same day and time). On each occasion, the participant will be given a capsule to swallow containing either 600mg sulpiride or a placebo sugar pill, according to a randomised, double blind procedure. Participants will commence the study tasks after 180 minutes have elapse (to coincide with peak drug levels) and will complete the tasks within 330 minutes. Observation will occur for a further 30 minutes.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000652370